04 September 2017 | News
With support from Ontario’s Jobs and Prosperity Fund, Apotex is investing in new manufacturing technology and processes that will expand the company’s product range and enhance productivity
Ontario, Canada is partnering with Canada based pharmaceutical company, Apotex Inc. to invest in new technology and product development at its Etobicoke, Ontario facility.
Shafiq Qaadri, MPP for Etobicoke North, and Yvan Baker, MPP for Etobicoke Centre, made the announcement recently on behalf of Brad Duguid, Minister of Economic Development and Growth.
Ontario is providing a grant of up to $8.25 million through the Jobs and Prosperity Fund. This is part of a larger overall investment by the company valued at $222.70 million. The project is scheduled for completion in 2022.
With support from Ontario’s Jobs and Prosperity Fund, Apotex is investing in new manufacturing technology and processes that will expand the company’s product range and enhance productivity.
Brad Duguid said, “Ontario's broad and innovative life sciences sector is a cornerstone of the province’s knowledge economy and also contributes to improving lives around the world. Through this strategic partnership, Apotex will boost its competitiveness, create jobs and reinforce its position as a key anchor company in Ontario’s life sciences cluster.”
Shafiq Qaadri commented, “Apotex has been part of the Etobicoke North community for many years now, and with this support from Ontario’s Jobs and Prosperity Fund it will be able to continue to develop affordable and quality medicine for the global market.”
Dr. Jeremy B. Desai, CEO and President, Apotex said, “As a proudly Canadian global pharmaceutical company, we take pride in our long history of investment in Ontario. From research and development, to manufacturing and packaging, our highly skilled workforce is key to delivering on our purpose of providing access to affordable, high quality and innovative healthcare solutions.”